Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05369403 · ClinicalTrials.gov registry record · Phase 3
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 86
- Enrollment target
NCT05369403 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 86 participants.
The verdict
NCT05369403, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 86 participants
- Enrollment target
Study Summary
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.
Interventions
- DRUG Lebrikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05369403
The ClinicalTrials.gov registry entry for NCT05369403 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lebrikizumab is the first listed.
NCT05369403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05369403 about?
NCT05369403 is a clinical study titled "A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab". The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.
What is the current status of trial NCT05369403?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 86 participants. The study started on 2022-12-19. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT05369403?
The interventions under investigation include: Lebrikizumab (DRUG).
Who is sponsoring clinical trial NCT05369403?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.